2. Search Result
Search Result
Results for "

DIO.

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

7

Fluorescent Dye

3

Biochemical Assay Reagents

9

Peptides

10

Natural
Products

5

Isotope-Labeled Compounds

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0969
    DiO
    20+ Cited Publications

    DiOC18(3); 3,3'-Dioctadecyloxacarbocyanine perchlorate

    		 Fluorescent Dye Others
    DiO is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
    DiO
  • HY-18341
    L-Thyroxine
    Maximum Cited Publications
    13 Publications Verification

    Levothyroxine; T4

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine
  • HY-B0346
    Propylthiouracil
    3 Publications Verification

    6-n-Propylthiouracil; 6-Propyl-2-thiouracil; PTU

    		 Environmental Pollutants Thyroid Hormone Receptor Endocrinology
    Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .
    Propylthiouracil
  • HY-18341B
    L-Thyroxine sodium
    10+ Cited Publications

    Levothyroxine sodium; T4 sodium

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium
  • HY-P10745
    Petrelintide

    ZP8396

    		 Amylin Receptor Metabolic Disease
    Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
    Petrelintide
  • HY-P10745A
    Petrelintide acetate

    ZP8396 acetate

    		 Amylin Receptor Metabolic Disease
    Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
    Petrelintide acetate
  • HY-12443
    PF-5006739

    		Casein Kinase Neurological Disease
    PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .
    PF-5006739
  • HY-151500
    JBSNF-000028 free base

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 free base
  • HY-18341A
    L-Thyroxine sodium salt pentahydrate
    10+ Cited Publications

    Sodium levothyroxine pentahydrate

    		 Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine sodium salt pentahydrate (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium salt pentahydrate
  • HY-13467
    AM-1638
    3 Publications Verification

    		 Free Fatty Acid Receptor Metabolic Disease
    AM-1638 is an orally active full agonist of GPR40 (EC50: 0.16 μM). AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocks Palmitate (HY-N0830)-mediated superoxide production and ER stress. AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%) .
    AM-1638
  • HY-160912
    ELOVL6-IN-5

    		ELOVL Metabolic Disease
    ELOVL6-IN-5 is an orally active and selective elongase enzyme of long-chain fatty acid family 6 (ELOVL6) inhibitor with IC50 values of 85 nM and 38 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-5 shows >60-fold selectivity over other ELOVL family enzymes (ELOVL1, 2, 3, 5) and no effect on other lipid synthesis enzymes like ACC1, ACC2. ELOVL6-IN-5 reduces hepatic fatty acid composition ratio of C18 to C16 in diet-induced obesity (DIO) and KKAy mice. ELOVL6 inhibition by ELOVL6-IN-5 does not improve insulin resistance. ELOVL6-IN-5 can be used for the research of metabolic disease .
    ELOVL6-IN-5
  • HY-18341R
    L-Thyroxine (Standard)

    Levothyroxine (Standard); T4 (Standard)

    		 Reference Standards Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (Standard) is the analytical standard of L-Thyroxine. This product is intended for research and analytical applications. L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine (Standard)
  • HY-14342
    MK-5046
    2 Publications Verification

    		 Bombesin Receptor Metabolic Disease
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    MK-5046
  • HY-114557
    NSC 90469

    3,5-Diiodo-L-thyronine

    		 JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen Metabolic Disease Inflammation/Immunology Endocrinology
    NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
    NSC 90469
  • HY-147318
    PBENZ-DBRMD

    		Apoptosis Cancer
    PBENZ-DBRMD is a potent iodothyronine deiodinase type 3 (DIO3) inhibitor. PBENZ-DBRMD has anti-proliferative activity and induces apoptosis. PBENZ-DBRMD can be used for cancer research .
    PBENZ-DBRMD
  • HY-18341S2
    L-Thyroxine-13C6

    		Thyroid Hormone Receptor Endogenous Metabolite Endocrinology
    L-Thyroxine- 13C6 is the 13C labeled L-Thyroxine . L-Thyroxine (Levothyroxine;T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine-13C6
  • HY-151500B
    JBSNF-000028 hydrochloride

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 hydrochloride
  • HY-W010669
    L-Thyroxine sodium xhydrate
    10+ Cited Publications

    Sodium levothyroxine

    		 Thyroid Hormone Receptor Endocrinology
    L-Thyroxine sodium xhydrate (Levothyroxine; T4) is a synthetic hormone in the treatment of hypothyroidism. DIO enzymes convert biologically active hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
    L-Thyroxine sodium xhydrate
  • HY-P10032
    NN1177

    NNC9204-1177

    		 GCGR GLP Receptor Cytochrome P450 Metabolic Disease
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .
    NN1177
  • HY-114340
    LEM-14

    		Histone Methyltransferase Apoptosis Cancer
    LEM-14 is a potent and selective NSD2 inhibitor with an IC50 of 132 µM. LEM-14 has very weak activitv against NSD1 and has no activity against NSD3. LEM-14 inhibits fibrotic gene expression in ND but not DIO BMDMs. LEM-14 combined with ionizing radiation (IR) enhances the apoptosis rate and reduces the colony-formation ability of CRC cells. LEM-14 exhibits enhanced anti-tumor efficacy in Balb/c nude mice bearing LoVo cell xenografts when combined with ionizing radiation. LEM-14 has the potential for the research of multiple myeloma and colorectal cancer .
    LEM-14
  • HY-18341F
    Biotin-(L-Thyroxine)

    		Thyroid Hormone Receptor Endogenous Metabolite Endocrinology
    Biotin-(L-Thyroxine) is the biotinylated L-Thyroxine (HY-18341). L-Thyroxine is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from Biotin-(L-Thyroxine) (T4) .
    Biotin-(L-Thyroxine)
  • HY-133876
    4-Di-16-ASP

    DiA

    		 Fluorescent Dye Others
    4-Di-16-ASP is a green fluorescent membrane dye. 4-Di-16-ASP is a lipophilic aminostyryl probe with a broad emission spectrum (can be detected with green, orange or even red filters). It is commonly used for neuronal membrane tracing (it diffuses faster than DiO) .
    4-Di-16-ASP
  • HY-151959
    FXR agonist 4

    		FXR Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
    FXR agonist 4
  • HY-151500A
    JBSNF-000028 TFA

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 TFA
  • HY-172661
    Kylo-0603

    		Thyroid Hormone Receptor Interleukin Related LDLR Infection Metabolic Disease
    KYLO-0603 is an orally active, selective THR-β agonist (EC50 : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
    Kylo-0603
  • HY-DY1010
    DiO (solution)

    		Fluorescent Dye Others
    DiO (solution) is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .
    Solvent and concentration: DMSO: 5 mM
    DiO (solution)
  • HY-138007
    SR-1903

    		ROR PPAR LXR Metabolic Disease Inflammation/Immunology
    SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
    SR-1903
  • HY-144287
    Glucokinase activator 3

    		Glucokinase Sodium Channel Metabolic Disease
    Glucokinase activator 3 is an orally active Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .
    Glucokinase activator 3
  • HY-P11321A
    IUB0271 hydrochloride

    acyl-GIP hydrochloride

    		 Insulin Receptor Metabolic Disease
    IUB0271 (acyl-GIP) hydrochloride is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 hydrochloride increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 hydrochloride can be used for type 2 diabetes mellitus (T2DM) and obesity research .
    IUB0271 hydrochloride
  • HY-P11321
    IUB0271

    acyl-GIP

    		 Insulin Receptor Metabolic Disease
    IUB0271 (acyl-GIP) is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
    IUB0271
  • HY-14342A
    (R)-MK-5046

    		Bombesin Receptor Metabolic Disease
    (R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    (R)-MK-5046
  • HY-151500C
    JBSNF-000028

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028
  • HY-129990
    Dios-Arg diTFA

    		Liposome Cancer
    Dios-Arg diTFA, a cationic lipid with an arginine-bearing headgroup, shows obvious double bond proton signals at around 5.2-5.3 ppm. Dios-Arg diTFA is used, coupled to DOPE, to bind siRNA and plasmid to for cationic LNPs for intracellular transport .
    Dios-Arg diTFA
  • HY-177297
    LCZ960

    NVP-LCZ960

    		 Glucokinase Metabolic Disease
    LCZ960 is an orally active glucokinase (GK) activator. LCZ960 stimulates GK activity in hepatocytes in vitro and stimulates glucose uptake in vivo through hepatic GK activation. LCZ960 lowers blood glucose in mice with diet-induced obesity (DIO). LCZ960 maintains normoglycemia and improves glucose tolerance in DIO mice and rats. LCZ960 stimulates glycogen synthase flux and increases hepatic glycogen turnover in rats. LCZ960 induces increased hepatic glycogen recycling. LCZ960 can be used to study high-fat diet-induced obesity and type 2 diabetes .
    LCZ960
  • HY-101699A
    AMG-076

    		MCHR1 (GPR24) Metabolic Disease
    AMG-076 is an orally bioavailable and selective MCHR1 antagonist. AMG-076 results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .
    AMG-076
  • HY-B0346R
    Propylthiouracil (Standard)

    6-n-Propylthiouracil (Standard); 6-Propyl-2-thiouracil (Standard); PTU (Standard)

    		 Thyroid Hormone Receptor Reference Standards Endocrinology
    Propylthiouracil (Standard) is the analytical standard of Propylthiouracil. This product is intended for research and analytical applications. Propylthiouracil (6-n-Propylthiouracil), a thioamide antithyroid agent, is an orally active thyroperoxidase and type-1 deiodinase (DIO1) inhibitor. Propylthiouracil can be used for the Graves disease and hyperthyroidism research .
    Propylthiouracil (Standard)
  • HY-18341BR
    L-Thyroxine sodium (Standard)

    Levothyroxine sodium (Standard); T4 sodium (Standard)

    		 Reference Standards Thyroid Hormone Receptor Endogenous Metabolite Endocrinology Cancer
    L-Thyroxine (sodium) (Standard) is the analytical standard of L-Thyroxine (sodium). This product is intended for research and analytical applications. L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine sodium (Standard)
  • HY-18341S1
    Thyroxine hydrochloride-13C6

    Levothyroxine-13C6; T4-13C6

    		 Isotope-Labeled Compounds Thyroid Hormone Receptor Endogenous Metabolite Endocrinology
    Thyroxine hydrochloride- 13C6 is the 13C-labeled L-Thyroxine. L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    Thyroxine hydrochloride-13C6
  • HY-101699
    AMG-076 free base

    		MCHR1 (GPR24) Metabolic Disease
    AMG-076 free base is an orally bioavailable and selective MCHR1 antagonist. AMG-076 free base results in significant reduction in body weight gain in nonobese mice fed a high-fat diet and in high-fat diet-induced obese (DIO) mice .
    AMG-076 free base
  • HY-W010669R
    L-Thyroxine sodium xhydrate (Standard)

    Sodium levothyroxine (Standard)

    		 Reference Standards Thyroid Hormone Receptor Endocrinology
    L-Thyroxine sodium xhydrate (Standard) is the analytical standard of L-Thyroxine sodium xhydrate. This product is intended for research and analytical applications. L-Thyroxine sodium xhydrate (Levothyroxine; T4) is a synthetic hormone in the treatment of hypothyroidism. DIO enzymes convert biologically active hormone (Triiodothyronine,T3) from L-Thyroxine (T4).
    L-Thyroxine sodium xhydrate (Standard)
  • HY-178857
    CB1 antagonist 6

    		Cannabinoid Receptor Metabolic Disease
    CB1 antagonist 6 (Compound 11jE2) is an orally active CB1R antagonist, with an IC50 value of 23 nM. CB1 antagonist 6 significantly reduces food intake and body weight, improves glucose tolerance and insulin resistance, and decreases serum ALT and AST levels in diet-induced obese (DIO) mice, demonstrating hepatoprotective effects. CB1 antagonist 6 can be used for the study of metabolic syndrome (obesity, diabetes) .
    CB1 antagonist 6
  • HY-18341S4
    L-Thyroxine-13C6-1

    Levothyroxine-13C6-1; T4-13C6-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Thyroid Hormone Receptor Endocrinology
    L-Thyroxine- 13C6-1 (Levothyroxine- 13C6-1; T4- 13C6-1) is a 13C labeled L-Thyroxine (HY-18341). L-Thyroxine (Levothyroxine; T4) is a synthetic hormone for the research of hypothyroidism. DIO enzymes convert biologically active thyroid hormone (Triiodothyronine,T3) from L-Thyroxine (T4) .
    L-Thyroxine-13C6-1
  • HY-P11262
    GUB021794

    		GLP Receptor Metabolic Disease
    GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .
    GUB021794
  • HY-RS03769
    DIO1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIO1 Human Pre-designed siRNA Set A contains three designed siRNAs for DIO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIO1 Human Pre-designed siRNA Set A
    DIO1 Human Pre-designed siRNA Set A
  • HY-RS22137
    Dio3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Dio3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dio3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dio3 Mouse Pre-designed siRNA Set A
    Dio3 Mouse Pre-designed siRNA Set A
  • HY-RS28658
    Dio3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Dio3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dio3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Dio3 Rat Pre-designed siRNA Set A
    Dio3 Rat Pre-designed siRNA Set A
  • HY-RS03771
    DIO3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIO3 Human Pre-designed siRNA Set A contains three designed siRNAs for DIO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIO3 Human Pre-designed siRNA Set A
    DIO3 Human Pre-designed siRNA Set A
  • HY-RS03770
    DIO2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIO2 Human Pre-designed siRNA Set A contains three designed siRNAs for DIO2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIO2 Human Pre-designed siRNA Set A
    DIO2 Human Pre-designed siRNA Set A
  • HY-165660S
    2,3-Dinor-6-ketoProstaglandinF1α-d9sodium salt

    2,3-Dio-6-ketoPGF1α-d9sodium salt

    		 Isotope-Labeled Compounds Others
    2,3-Dinor-6-ketoProstaglandinF1α-d9 (2,3-Dio-6-ketoPGF1α-d9) sodium saltis deuterium labeled 2,3-Dinor-6-ketoProstaglandinF1α(sodium salt) .
    2,3-Dinor-6-ketoProstaglandinF1α-d9sodium salt
  • HY-N3795
    Thiophene E

    Echinoynethiophene A; Thiophene A dio

    		 Others Others
    Thiophene E (Echinoynethiophene A) is a natural product .
    Thiophene E

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: